In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Bausch Health Companies Inc (NYSE: BHC). The company’s shares opened today at $22.41.
Rivkind Koffler commented:
“We raise our PT to $35 from $31 based on continued margin improvement that may drive 3.2% incremental improvements in EBITDA by 2022. We reiterate our Buy rating.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 11.9% and a 47.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Bausch Health Companies Inc is a Hold with an average price target of $24, representing a 7.1% upside. In a report issued on August 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $32 price target.
.
See today’s analyst top recommended stocks >>
Based on Bausch Health Companies Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $873 million. In comparison, last year the company earned revenue of $2.23 billion and had a GAAP net loss of $38 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
